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ABSTRACT

In this paper we explore the impact of electronic commerce on the industry structure and market power allocation of
China’s pharmaceutical industry. Firstly, we describe the overall characteristics of the pharmaceutical Industry in
general. Secondly, we develop a value chain based framework of analysis for China’s pharmaceutical industry. We
divide the pharmaceutical industry value chain into three tiers: the initial market, the middle market and the end market.
Based on these works, we analyze the profound impacts of Electronic Commerce on the transformation of China’s
pharmaceutical Industry, with particular emphasis on the evolution of market structure and the re-allocation of market
power due to the introduction of E-Commerce procedures.
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1. INTRODUCTION
In this paper we explore the impact of electronic
commerce on the industry structure and market power
allocation of China’s pharmaceutical industry. Firstly,
we will describe the overall characteristics of the
pharmaceutical Industry in general. Pharmaceutical
manufacturers in the market could be divided into two
types: pioneer firms and genetic (imitator) firms, and
most of the Chinese pharmaceutical manufacturers
belong to the second group. As for the pharmaceutical
products, after the introduction of the Pharmaceutical
Regulation Rules, the taxonomy of medical products in
China is becoming similar to that of the US, which
consists of prescription drugs and over-the counter
drugs. As a result, the market for medical products
could generally be divided into prescription market and
over-the-counter market.
Secondly, we develop a value chain based framework of
analysis for China’s pharmaceutical industry. We divide
the pharmaceutical industry value chain into three tiers:
the initial market, the middle market and the end market.
We focus on the situation of the industry structures and
market conditions at present. Then in the last part of the
paper, we analyze the profound impacts of Electronic
Commerce on the transformation of China’s
pharmaceutical Industry, with particular emphasis on the
evolution of market structure and the re-allocation of
market power due to the introduction of E-Commerce
procedures. We conclude that pharmaceutical
manufacturing industry will achieve a new stable
structure with smaller firm quantity and stronger firm
power. In wholesaling industry only a few big firms
would exist in the national market. The three-class agent
system may disappear. The relative market power of
retailers will strengthen in the initial market that may
result in monopsony. And The B2C in pharmaceutical
retailing industry would pose a chance to re-allocate the

market share between hospitals and pharmacies.
2.

THE OVERVIEW OF PHARMACEUTICAL
INDUSTRY

Most of the pharmaceutical markets in the world are
highly monopolized. In 2000 the top ten pharmaceutical
manufacturers’ market share was 50% in the world. In
comparison with the word market, Chinese
pharmaceutical market is highly competitive with a high
number of manufacturers and distributors. That’s the
peculiarity of Chinese pharmaceutical industry, which
we will explicate later. Firstly we’re looking for some
characteristics of the pharmaceutical Industry in
general.
The pharmaceutical manufacturers in the market could
be divided into two types: pioneer and genetic or
imitator firms. The pioneer firms are companies who
undertake research and development to discover new
drugs and bring them to market. They have the patent
rights of these new drugs, which ensure them to be the
monopoly before the patent expiration. But the R&D
and marketing take long time and millions of dollars.
That leads to a much higher price of the pioneer firm’s
product compared with that of the imitators’. Some
famous pioneer firms in the world include Merck and
Dupont, ect. Only a few of the Chinese pharmaceutical
manufacturers belong to this group, such as
Tongrentang. The genetic or imitator firms are smaller
and don’t do much R&D themselves. They produce
some “bioquivalent” products to the original branded
products after the patent expiration, and their prices are
usually much lower. Most of the Chinese
pharmaceutical manufacturers belong to this group.
As for the pharmaceutical products, after the
introduction of the Pharmaceutical Regulation Rules,
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the taxonomy of medical products in China is becoming
similar to that of the US, which consists of prescription
drugs and over-the counter drugs. The over- the-counter
(OTC) drugs could be bought in any pharmacy. Such as
vitamins and parts of the antibiotics. This kind of drug’s
demand is great but no stable, and it’s profits usually are
not very high. The total revenue in the US drug market
in 2002 was 214.7 million dollars, the OTC only took
57.8 million dollars in it. And the sale of prescription
drugs is controlled strictly. The buyers have to hold a
prescription by doctors and can only buy the catalog and
dose of the drug listed on the prescription. This kind of
drug has much more danger for normal people, but its
effect is better to the special patients. In fact the
prescription drugs take the main market share and have
stable demand. As a result, the market for medical
products could generally be divided into prescription
market and over-the-counter market. One of the most
important characters of prescription drug is that the end
consumers have less freedom to choose the products at
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their will. Instead, doctors or apothecaries make their
choices including the category of drugs and also brands
within the category. The unique type of principal agent
relationship causes problems in the market such as price
insensitivity in the retailing market, asymmetric
information, agency problem, necessary for regulation
etc.
3.

A MARKET TAXONOMY OF THE CHINESE
PHARMACEUTICAL INDUSTRY AND
MARKETS ANALYSIS

3.1 Chinese Pharmaceutical Industry Value Chain
Though the revolutions in Chinese pharmaceutical
industry push the industry closer and closer to the
international standards. The value chain in China has
some special characters. See Figure1.
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Patient
Normal
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Figure 1 Chinese pharmaceutical industry Value chain
For example, there is no company like the PMB in US.
In China the medicine-governing department and
insurance companies decide what kind of drugs should
be included in the insurance list. Another important
feature is that the hospitals also sell medicines as the
normal
pharmacies
in
China.
So
Chinese
pharmaceutical retailers include both the pharmacies
and hospitals. The hospitals’ market share is over 80%
in the drug wholesale market. They are the most
valuable customers to the wholesalers and
manufacturers. In fact, in the prescription market the
hospital nearly take almost the whole market share. But
in the OTC market, the pharmacy’s market share is
increasing these years.
3.2 A Market Taxonomy Based on Value Chain —
Three-Class Markets
For convenience we divide the value chain into
three-class markets and analyze them independently.
The buyer in the former class market would turn to be
the seller in the latter market. In this paper all the
medicine products are thought to be the same (but the
prescription and over-the-counter still have some
difference which will be mentioned later). We define
three-class markets as the initial market, the middle
market and the end market, in which the sellers and
buyers are manufacturers and wholesalers, wholesalers
and retailers, retailers and consumers.

3.3 The Analysis of the Three Markets
3.3.1

The Initial Market

This market is the first market of pharmaceutical
products. The manufacturers are the sellers, and the
buyers are wholesalers.
At present there are more than 6000 pharmaceutical
manufacturers in China. But most of them produce only
one or several main products. The average firm size is
very small. The biggest one’s sale revenue is equal to
1% of the sale revenue in US. The isolation of different
regions market is very notable. The firms are competing
intensely and there’s no real industry leader till now.
Another feature is the manufacturers simply focus on
production but don’t pay much attention to the
distribution channel. So they highly relay on the
downstream firms who handle the market channel.
That’s why their market power is weak facing the
distributors and agents.
We subdivide the manufacturers into four types and
observe the top ten firms’ market share from 1996-2002
(See Figure 2). It’s clear that the market concentration
rate is low. In 2002, the four subdivided markets’ CR10
are 44%, 32%, 18% and 16%. Considering the fact that
few of the top ten firms in the four subdivided types are
inter-industry. The market concentration of the whole
pharmaceutical manufacture is much lower.
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Figure 2 The total market shares of the top ten
pharmaceutical manufacturers
As for the wholesalers, the situation is similar. Now
there are more than 16000 pharmaceutical wholesalers
in China. Only 5% of them have got the revenue per
year over ￥ 20,000,000. In 2002, there are 17
pharmaceutical wholesalers on the list of China top 500
wholesalers. The total market share of the 17 firm is
25.88%, CR10=18.98%. Compared with the situation in
the US and Germany, the market concentration is very
low. See Figure3
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Figure 3 The CR3s of three countries’ pharmaceutical
wholesale industries
To sum up, in the initial market there are a great number
of manufacturers and most of them have little market
power which leads to a low market concentration. The
barriers to entry are actually lower than in some other
mature product markets. Most of Chinese firms are
generic firms whose R&D inputs and levels are
relatively low. To the wholesalers who are the buyers in
the initial market, there are low barriers to entry. In such
a situation both the buyers and sellers do not have great
bargain power. But in the regional markets some
wholesalers have relatively high monopoly power due
to the isolation of the markets from competition.
3.3.2

But the situation is changing in these years due to the
newly adopted policy of the hospital procurement
bidding system. Though this bidding system has not
been fledged and adopted by all the firms in the industry.
It has shown a very attractive tendency. It plans to take
all the manufacturers, wholesalers and retailers together
in one system including E-Commerce system and EDI.
All the information about the drugs such as price,
producer, agent or wholesalers will be supported in the
E-Commerce system. The retailers would be able to
choose the catalog, brand, and the wholesaler as the
supplier of one product directly and efficiently. And the
wholesalers and retailers could search and exchange the
information through EDI. Now the government is trying
to develop and propel this pharmaceutical industry
electronic business system.
3.3.3

The end market

The sellers and buyers in this market are retailers and
consumers. The total demand of the pharmaceutical
products is very stable and has low price elasticity. The
agent problem is very marketable in this market. That
gives the hospital an unshakable advantage.

95%

US

who are the buyers including two groups: pharmacies
and hospitals. In theory the two kinds of retailers are the
same, but actually the hospitals have obvious advantage,
especially in the prescription drug market. They are the
most important customers to the wholesalers. This tier
of market has been very inefficient because of the
wholesalers’ iniquitous performance.

The Middle Market

The wholesalers are sellers in this market. The retailers

The demand of every consumer depends on the
condition that the consumer is in. If the consumer is in
healthy condition, his demand elasticity is zero but the
demand is zero also. If the consumer is in ill condition,
the demand isn’t zero with a very small elasticity. We
infer it’s a concave function in a limited area whose slop
changes from zero to infinity. So the end consumer’s
demand function could be written as a random variable
D(ω)，ω∈(ω0，ω1)，ω0=（Healthy），ω1=（Sick）, that’s
the most simple space and the ω1 could be subdivided
farther. Set P as price, Q as quantity, we have
D(ω0) = 0
(1)
D(ω1) = Q(P) with Q’(P)<0 and |Q’’(P)|<0. (2)
4

APPLICATION OF E-COMMERCE IN THE
CHINESE PHARMACEUTICAL INDUSTRY

Now the E-Commerce of pharmaceutical industry is just
at the beginning in China. The trading amount is a quite
small proportion of the big market. E-Commerce
emerges mainly in B2B model. And there hasn’t been an
efficient regulation to this new model of business. But
it’s growing up in a remarkable speed. More and more
companies have recognized the coming revolution from
the new market factor and are going to join the process
whether they wish it or not. With the government’s
effort, there is no doubt that the Internet will be a crucial
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factor of the revolution of pharmaceutical industry in
China.

competitive advantage from E-Commerce. That may
lead to a revolution in the industry.

In China some successful B2B models are coming in
sight. Some of them try to build an information center
and industry database such as www.cpi.ac.cn,
www.gm.net.cn. Some of them focus on the
E-commerce Service Provide (ESP) like www.e135.com,
yy.18-china.com. The main customs of these businesses
are pharmaceutical manufacturers, wholesalers or agents,
pharmacies and hospitals. The most important
investment comes from the relevant departments in
government and companies. Though their market share
is not high, the potentiality of them is very large. Such
as www.e135.com, the trading amount in the first 8
months went beyond 15 million Yuan. The amount at
the end of 2000 had reached hundreds of million Yuan.

But what’s the problem with the small firms? Why we
say the winners should be only the middle ones? That’s
the special situation in China. Now all the
pharmaceutical manufacturers are facing the GMP
acceptance. To reach this level the firms have to pay
much cost to improve the production conditions,
otherwise they will have to quit. And in the new hospital
procurement bidding system, some firms are usually not
the chosen ones. Based on all the policies of recent
years, we infer that the government wants to push the
small firms who do not have competitive advantages out
of this too-crowded industry. That’s the first step to
solve the problems in the ex-competitive pharmaceutical
industry. The new competitive advantage supported by
Internet can’t fight with the government. Additionally
the small firms in China are highly relied on the local
markets. But the Internet will break the local market and
bring all the middle and large firms into every regional
market. That will be another hit to the small firms. So
the winners would only be the middle firms who could
catch this chance.

5

THE PROFOUND IMPACT ON CHINESE
PHARMACEUTICAL INDUSTRY OF
E-COMMERCE: THE INDUSTRY AND
MARKET POWER

The E-Commerce of pharmaceutical industry, especially
the B2B, is being adopted and going to be the new focus
of the Chinese E-Commerce with the support of
government. B2C, which has been popular in US, is also
a hot point in China. These new business models are the
most immediate impacts of the Internet.
Relatively to the B2C, B2B is more practical in the
initial market and middle market and may break down
the original market structure. The Chinese market is has
some remote regions that are inaccessible to the Internet.
The barriers to entry of the regional markets are
becoming lower, which will lead to emergence of more
enters. So the regional monopoly will face more
potential competitors and the small firms will have the
ability to enter more markets. The result is the changes
of the industry structure and the market power
allocation of both upstream and downstream firms.
5.1 Manufacture Industry
In the manufacture industry the beneficiary would go to
the middle firms. The large firms have paid great cost to
get the national market share during the past time. But
with the Internet the other smaller firms could get into
the national market in a much cheaper way. That’s
impossible in the no-Internet days. So their prices could
be much lower than that of the large firms’, which
makes them to be serious competitors to the large firms.
Though the large firms could apply the Internet to
decrease their cost too. The past cost and huge
traditional market nets will be their disadvantages in the
Internet time. There will not only be the finance
problem but also the management problems for
transformation. And there don’t exit such problems for
the middle and small firms. They only get a new

To conclude, The application of B2B in pharmaceutical
industry will lead to a new structure: the small firms
without competitive advantage will quit the market;
some middle firms will have great development by this
chance; the big firms have to undergo some revolution
to deal with the new competitors to protect their market
shares. More combinations will emerge for expansion,
some of them will go beyond the regions.
5.2 Wholesaling Industry
In the retailing industry the Internet breaks down the
limit of regions that is two-way relatively. That means
in both the upstream and downstream markets the
wholesalers faces the region limitation. This two-way
region limitation may be one important reason for the
low market concentration rate.
Comparing with the manufacture industry, the focus in
retailing industry is the distribution channels. The
Internet will break all the market bounders. That means
every wholesaler will face incredible numbers of
downstream retailers, which is impossible in the
traditional market. Then every firm will have chances to
win some new customers and lose some old costumers.
That will lead to a higher competition. But the
government will play an important role here. Similarly
to the manufacture industry, new hospital procurement
bidding system will help the powerful firms get more
market shares in the future, even result in nature
monopoly. There will be some problems of this method,
such as the region limitation in retailing market. But the
Internet would help overcome it. All the firms who win
the bidding will come to one national market by the
Internet and compete with each other. So from both
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the policy and the technology perspectives, we suggest
that the government contracts the market and the
Internet connects the market.

and prescription drugs respectively.
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6

CONCLUSIONS: SOME PREDICT TO THE
FUTURE OF CHINESE PGARMACEUTICAL
INDUSTRY

At last the pharmaceutical manufacturing industry will
achieve a new stable structure with smaller number of
firms and stronger firm power that will lead to a higher
market concentration. The market won’t be divided into
many regional markets with more beyond-regions
companies who will compete together in the national
market. Comparing with before, the manufacturers’
market power will strengthen, but the downstream firms
change also, the relative market power depends on both
sides. In the wholesaling industry only several big firms
would exist in the national market. The three-class agent
system may disappear. The relative market power of
retailers will strengthen a lot in the initial market that
may result in a monopsony situation. The B2C business
model in the pharmaceutical retailing industry denotes a
chance to re-allocate the market share between hospitals
and pharmacies. The final structures may be the
pharmacies and hospitals handle the over-the-counter
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